AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28886351
Drug: Dexamethasone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (10 or 30 mg)
Trial: 30845095
Drug: Dexamethasone (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (10 mg)
Trial: 30845095
Drug: Dexamethasone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (30 mg)
Trial: 29023215
Drug: Monthly Denosumab
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly Denosumab
Trial: 29023215
Drug: Monthly Zoledronic
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly Zoledronic Acid (ZA)
Trial: 17890830
Drug: Quality improvement
RxNorm normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Quality improvement (QI) programs involving medication or psychotherapy
Trial: 15126132
Drug: Bendroflumethiazide (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendroflumethiazide (2.5 mg)
Trial: 11669431
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg hyperbaric bupivacaine with added fentanyl 20 microg (group BF)
Trial: 11669431
Drug: 12.5 mg
RxNorm normalized name: rutin 12.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5 mg hyperbaric bupivacaine alone (group B)
Trial: 7985742
Drug: SP/CQ (treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP/CQ (treatment dose of sulfadoxine-pyrimethamine followed by weekly chloroquine prophylaxis)
Trial: 7985742
Drug: SP/SP (two-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SP/SP (two-dose sulfadoxine-pyrimethamine regimen)
Trial: 30136704
Drug: Continuous Renal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Renal Replacement Therapy (CRRT) in addition to conventional therapy
Trial: 10910028
Drug: Atorvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (40 mg daily)
Trial: 18363314
Drug: Methylphenidate (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate (mean daily dose of 36.7 +/- 11.2 mg over > or = 26 days)
Trial: 12029450
Drug: Colloid infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colloid infusion
Trial: 12029450
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no colloid infusion)
Trial: 10999121
Drug: EPO therapy
RxNorm normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: EPO therapy (40 U/kg biweekly for 6 weeks)
Trial: 7261664
Drug: placebo creams
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo creams
Trial: 28526920
Drug: semaglutide 1.0
RxNorm normalized name: SEMAGLUTIDE 1.0 mg in 0.5 mL SUBCUTANEOUS INJECTION, SOLUTION [WEGOVY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: semaglutide 1.0 mg once-weekly
Trial: 23374910
Drug: Hotspot-targeted interventions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hotspot-targeted interventions including larviciding, focal screening and treatment, distribution of long-lasting insecticide-treated nets, and indoor residual spraying.
Trial: 19320633
Drug: Baseline measures
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline measures of perceived stress, drinking severity, psychiatric comorbidity, self-efficacy, craving, and positive treatment outcome expectancies
Trial: 19116389
Drug: Beta carotene
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta carotene (50 mg every other day)
Trial: 15096081
Drug: Sertraline (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sertraline (titrated up to 50-150 mg/day)
Trial: 15096081
Drug: Paroxetine (titrated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (titrated up to 40-60 mg/day)
Trial: 12106936
Drug: Spironolactone (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (12.5 to 50 mg/day)
Trial: 27327441
Drug: Spironolactone (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone (50 mg)
Trial: 9641366
Drug: Thyroxine 0.1
RxNorm normalized name: LEVOTHYROXINE 0.1MG/ML ORAL SOLN UD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroxine 0.1 mg daily
Trial: 7943696
Drug: Tubocurare (0.125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tubocurare (0.125 mg.kg‐1 or 0.25 mg.kg‐1)
Trial: 7943696
Drug: Suxamethonium (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Suxamethonium (1 mg.kg‐1)
Trial: 3287770
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of pirenzepine (75 mg/day) and cimetidine (400 mg at bedtime)
Trial: 3287770
Drug: Cimetidine monotherapy
RxNorm normalized name: Cimetidine
DrugBank: Cimetidine (DB00501)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cimetidine monotherapy (1000 mg/day)
Trial: 31888764
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (no cerebral oxygenation monitoring)
Trial: 15163331
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no glucocorticoid treatment)
Trial: 24699430
Drug: Standard memory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard memory therapy provided in the rehabilitation center
Trial: 24113708
Drug: High-repetition, moderate-intensity
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-repetition, moderate-intensity resistance training (n = 12) for 12 weeks, performed twice a week for 75 minutes per session.
Trial: 19808135
Drug: Modafinil 300
RxNorm normalized name: Modafinil
DrugBank: Modafinil (DB00745)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Modafinil 300 mg/d
Trial: 16807617
Drug: Eprosartan mesylate
RxNorm normalized name: Eprosartan Mesylate
DrugBank: Eprosartan (DB00876)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eprosartan mesylate 600 mg once daily
Trial: 16807617
Drug: Eprosartan mesylate
RxNorm normalized name: Eprosartan Mesylate
DrugBank: Eprosartan (DB00876)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eprosartan mesylate 600 mg once daily plus HBPM
Trial: 8418225
Drug: Octreotide at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide at a dosage of 0.1 mg subcutaneously twice per day for 3 days
Trial: 8418225
Drug: Loperamide 4
RxNorm normalized name: loperamide 0.4 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide 4 mg orally initially and then 2 mg every 6 hours for 3 days
Trial: 30516088
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard administration instructions)
Trial: 28854956
Drug: Ultra-low dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultra-low dose RTX (1×500 mg or 1×200 mg)
Trial: 28854956
Drug: Standard low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard low dose RTX (1×1000 mg)
Trial: 20931328
Drug: Pentagastrin (cholecystokinin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentagastrin (cholecystokinin type-2 receptor agonist)
Trial: 20931328
Drug: Morphine (pre-conditioning)
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine (pre-conditioning)
Trial: 20931328
Drug: Naloxone (μ-opioid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (μ-opioid receptor antagonist)
Trial: 18814906
Drug: Short-acting human
RxNorm normalized name: Short-acting sulfonamides
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-acting human insulin (1 unit/kg)
Trial: 20929566
Drug: Malaria intervention
RxNorm normalized name: Plasmodium malariae
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Malaria intervention (intermittent screening and treatment of malaria)
Trial: 16154017
Drug: Amlodipine-based combination
RxNorm normalized name: Amlodipine free base
DrugBank: Amlodipine (DB00381)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amlodipine-based combination drug regimen
Trial: 16154017
Drug: Atenolol-based combination
RxNorm normalized name: Atenolol
DrugBank: Atenolol (DB00335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atenolol-based combination drug regimen
Trial: 14698800
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg buprenorphine per day
Trial: 12039619
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg buprenorphine per day
Trial: 12039619
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg buprenorphine per day
Trial: 9569110
Drug: Intravesical BCG
RxNorm normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical BCG therapy (81 mg) in Group 1
Trial: 9569110
Drug: Intravesical BCG
RxNorm normalized name: BCG, live, Tice strain
DrugBank: Bacillus calmette-guerin substrain tice live antigen (DB10343)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravesical BCG therapy (54 mg) in Group 2
Trial: 8306416
Drug: Mitomycin 20
RxNorm normalized name: mitomycin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitomycin 20 mg/m2 only
Trial: 8306416
Drug: Mitomycin 20
RxNorm normalized name: mitomycin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mitomycin 20 mg/m2 after pretreatment with WR-2721, 910 mg/m2
Trial: 3189495
Drug: Blu Blocker
RxNorm normalized name: Blu-Kote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blu Blocker
Trial: 30649344
Drug: Feeding sows
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feeding sows once daily at 1530 h
Trial: 30649344
Drug: Control (Feeding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Feeding sows once daily at 0730 h)
Trial: 30649344
Drug: Feeding sows
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Feeding sows daily at 1130 h
Trial: 27545697
Drug: Colistin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colistin plus rifampicin (not detailed in dosage or duration)
Trial: 19145637
Drug: Daming capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daming capsule (DMC) 2 g b.i.d. for 6 weeks
Trial: 19145637
Drug: Pravastatin 10
RxNorm normalized name: pravastatin 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pravastatin 10 mg o.d. for 6 weeks
Trial: 17325925
Drug: Iodixanol (320
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iodixanol (320 mg Iota/ml) used in MDCTA
Trial: 15505151
Drug: Botulinum neurotoxin
RxNorm normalized name: Botulinum neurotoxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botulinum neurotoxin (BoNT) type A injections into the submandibular salivary glands
Trial: 15342830
Drug: Scopolamine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine treatment
Trial: 7985248
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UH), dextran, or vitamin K-antagonists
Trial: 2968595
Drug: Simvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (40 mg/day) for 12 weeks
Trial: 2968595
Drug: Simvastatin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (40 mg/day) + cholestyramine
Trial: 2968595
Drug: Cholestyramine (with
RxNorm normalized name: cholestyramine (with sugar) ORAL POWDER (GRAM)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholestyramine (with simvastatin 20 mg/day)
Trial: 24636808
Drug: Lactobacillus reuteri
RxNorm normalized name: Lactobacillus reuteri
DrugBank: Lactobacillus reuteri (DB14224)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus reuteri probiotic preparation
Trial: 23576138
Drug: Pemetrexed plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed plus Oxaliplatin (500 mg/m² Pemetrexed + 100 mg/m² Oxaliplatin)
Trial: 23576138
Drug: Pemetrexed plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pemetrexed plus Cisplatin (500 mg/m² Pemetrexed + 75 mg/m² Cisplatin)
Trial: 18775035
Drug: Enhanced information
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced information regarding life-sustaining treatment alternatives
Trial: 16768770
Drug: Peritonectomy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peritonectomy with heated intraperitoneal chemotherapy
Trial: 11805764
Drug: Rocuronium (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium (1.0 mg/kg)
Trial: 11805764
Drug: Vecuronium (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium (0.15 mg/kg)
Trial: 7786375
Drug: Usual rotation
RxNorm normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual rotation on general medicine wards (69 students)
Trial: 2120178
Drug: Temafloxacin 300
RxNorm normalized name: temafloxacin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temafloxacin 300 mg twice daily for ten days
Trial: 2120178
Drug: Temafloxacin 600
RxNorm normalized name: temafloxacin 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Temafloxacin 600 mg twice daily for ten days
Trial: 27486817
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Sm-153-EDTMP and PSA-TRICOM vaccine
Trial: 22520644
Drug: Letrozole 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Letrozole 7.5 mg daily for 3 days prior to the abortion
Trial: 18819444
Drug: New high-cost
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New high-cost antiepileptic drugs
Trial: 3521103
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg cimetidine b.i.d.
Trial: 3521103
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg cimetidine nocte
Trial: 26832653
Drug: Levofloxacin Sequential
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin Sequential Therapy (LS): lansoprazole and amoxicillin for the first 5 days, followed by lansoprazole, levofloxacin, and metronidazole for another 5 days
Trial: 26832653
Drug: Levofloxacin Triple
RxNorm normalized name: Levofloxacin
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin Triple Therapy (LT): lansoprazole, amoxicillin, and levofloxacin for 10 days
Trial: 21835900
Drug: Methylprednisolone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone (30 mg/kg in the cardiopulmonary bypass prime, 500 mg IV bolus following the final circulatory arrest, and 250 mg IV bolus 36 h after surgery)
Trial: 20627877
Drug: Fentanyl infusion
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl infusion (bolus dose of 1 microg kg(‐1) followed by continuous infusion of 0.5 microg kg(‐1) h(‐1))
Trial: 20627877
Drug: Fentanyl infusion
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl infusion (bolus dose of 2 microg kg(‐1) followed by continuous infusion of 1 microg kg(‐1) h(‐1))
Trial: 16164393
Drug: TNF‐α antagonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF‐α antagonists (infliximab, etanercept, adalimumab)
Trial: 16164393
Drug: Screening procedures
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Screening procedures for potential recipients of TNF‐α antagonists
Trial: 11322864
Drug: Prolonged antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged antiplatelet therapy
Trial: 2648788
Drug: Ketanserin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin (20 mg twice daily for 1 week, followed by 40 mg twice daily for 3 weeks)
Trial: 29932581
Drug: Modified ventilation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified ventilation mode with inversion of the respiratory cycle and high-level application of PEEP titration
Trial: 21435093
Drug: 14-day sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day sequential therapy (esomeprazole and amoxicillin for 7 days followed by esomeprazole, clarithromycin, and metronidazole for 7 days)
Trial: 17595593
Drug: Low-dose transdermal
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose transdermal estradiol (E2)/norethisterone acetate (NETA) patches (Estalis 25/125)
Trial: 17595593
Drug: Low-dose oral
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose oral E2/NETA (Activelle)
Trial: 9544873
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg of trandolapril
Trial: 9544873
Drug: 240 mg
RxNorm normalized name: aspirin 240 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 240 mg of verapamil SR
Trial: 9544873
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of 4 mg of trandolapril and 240 mg of verapamil SR
Trial: 8291491
Drug: 0.4% stannous
RxNorm normalized name: Stanimax 0.4% Stannous Fluoride Dental Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4% stannous fluoride gel (SnF2) used twice daily for 18 months
Trial: 2566736
Drug: Adrenaline plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adrenaline plus YAG laser therapy
Trial: 30678679
Drug: Outpatient psychiatric
RxNorm normalized name: INVESTIGATIONAL DRUGS FOR PSYCHIATRIC DISEASE,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Outpatient psychiatric treatment for clinical mental disorder
Trial: 30678679
Drug: Preventive cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preventive cognitive behavioural therapy for subclinical conditions
Trial: 16715781
Drug: Fluoxetine tablets
RxNorm normalized name: Fluoxetine Tablets
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine tablets (test)
Trial: 16715781
Drug: Fluoxetine capsules
RxNorm normalized name: Fluoxetine Capsules
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine capsules (reference)
Trial: 9252131
Drug: Loperamide (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loperamide (8 mg, ingested 13 and 4 hours before the meal)
Trial: 8375421
Drug: Flurbiprofen 50
RxNorm normalized name: flurbiprofen 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 50 mg twice daily
Trial: 3752983
Drug: Aztreonam (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aztreonam (2 g intravenously every 6 hours for 21 doses)
Trial: 31947628
Drug: Policaptil Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Policaptil Gel Retard (PGR)
Trial: 29707866
Drug: Dorzagliatin 75
RxNorm normalized name: Dorzagliatin
DrugBank: Dorzagliatin (DB15123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzagliatin 75 mg BID
Trial: 29707866
Drug: Dorzagliatin 75
RxNorm normalized name: Dorzagliatin
DrugBank: Dorzagliatin (DB15123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dorzagliatin 75 mg QD
Trial: 26984807
Drug: Topiramate administered
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate administered once a night at a dose of 2 mg/kg/day
Trial: 26984807
Drug: Topiramate administered
RxNorm normalized name: Topiramate
DrugBank: Topiramate (DB00273)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Topiramate administered twice a day at a dose of 4 mg/kg/day
Trial: 20103825
Drug: High-quality RCTs
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-quality RCTs not sponsored by pharmaceutical companies
Trial: 17578905
Drug: Remifentanil pharmacokinetics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil pharmacokinetics
Trial: 12029630
Drug: 7.5 mg
RxNorm normalized name: biotin 7.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7.5 mg losartan
Trial: 10220630
Drug: Intravenous metoprolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous metoprolol 5 mg x 3 plus 5 mg morphine
Trial: 10220630
Drug: Intravenous placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous placebo plus 5 mg morphine
Trial: 7778826
Drug: Azathioprine or
RxNorm normalized name: azathioprine Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine or 6-mercaptopurine therapy
Trial: 7778826
Drug: Continuation of
RxNorm normalized name: varenicline
DrugBank: Varenicline (DB01273)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuation of therapy for at least 17 weeks
Trial: 7778826
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose of azathioprine
Trial: 7778826
Drug: Increased cumulative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased cumulative dose
Trial: 27711088
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tryptophan, Satureja montana, Tribulus terrestris, Phyllanthus emblica extracts (1 tablet per day for 3 months)
Trial: 27711088
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tryptophan, Satureja montana, Tribulus terrestris, Phyllanthus emblica extracts